Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
engineered Clostridium butyricum GLP-1
- Development stage
- Unknown
- Lead developer
- Affiliated Reproductive Hospital of Jiangxi University of Traditional Chinese Medicine
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Engineered Clostridium butyricum GLP-1 is an orally administered live biotherapeutic product (LBP) consisting of a genetically modified strain of the probiotic bacterium *Clostridium butyricum* engineered to express and secrete glucagon-like peptide-1 (GLP-1). Developed by the Reproductive Hospital Affiliated to Jiangxi University of Traditional Chinese Medicine, this therapeutic approach leverages the gut-colonizing capabilities of *C. butyricum* to provide a continuous, localized delivery of GLP-1 within the gastrointestinal tract. The secreted GLP-1 acts as an agonist at the glucagon-like peptide 1 receptor (GLP1R), which promotes satiety, slows gastric emptying, and improves insulin sensitivity. This modality aims to overcome the limitations of injectable GLP-1 receptor agonists by offering a non-invasive, oral delivery system that potentially modulates the gut microbiome while providing metabolic benefits. It is currently under investigation in clinical trials (e.g., ChiCTR2500104877) for the treatment of obesity.
- Other names
- Engineered GLP-1–Secreting Clostridium butyricumGLP-1-secreting Clostridium butyricumGLP1-secreting Clostridium butyricumGLP 1-secreting Clostridium butyricum
02
Targets
Beyond the preview
Go deeper on engineered Clostridium butyricum GLP-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on engineered Clostridium butyricum GLP-1.